Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314625 | 1.00 | L3MBTL1 (0.34) | L3MBTL1KDM4EALDH1A1KDM1APOLB | |
| SCHEMBL1974974 | 0.87 | HCRTR1 (0.32) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL1974977 | 0.87 | HCRTR1 (0.32) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL314975 | 0.81 | SLC6A2 (0.32) | POLBGAA | |
| SCHEMBL314974 | 0.81 | SLC6A2 (0.32) | POLBGAA | |
| SCHEMBL2413274 | 0.81 | NPC1 (0.32) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2413277 | 0.81 | NPC1 (0.32) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1973660 | 0.81 | FURIN (0.36) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL314853 | 0.81 | CYP2A6 (0.39) | KDM4EALDH1A1POLB | |
| SCHEMBL314854 | 0.81 | CYP2A6 (0.39) | KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
| EP-2066683-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037922-A1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | L3MBTL1 2229/4885KDM4E 1220/4885ALDH1A1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.